ReviewTherapeutic advances in gastroenterology2025
Contemporary approaches in the peri-endoscopic management of antithrombotic agents: current paradigms, challenges, and prognostications.
Review in Therapeutic advances in gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the increasing prevalence of endoscopic procedures, peri-endoscopic management of antithrombotic agents remains challenging due to inconsistent guideline adherence. This review highlights barriers to suboptimal guideline adherence, which include inadequate guideline education, delayed regional guideline updates, ambiguous anticoagulation responsibility, drug cost disparities, and uneven international resource allocation. Proposed strategies to improve compliance include: (1) Enhanced education for physicians and patients to align practices with evidence-based recommendations; (2) Digital tools such as clinical decision aids to standardize risk stratification and medication management; (3) Unified antithrombotic management teams to clarify responsibilities and reduce inter-specialty discrepancies; and (4) International collaboration to harmonize guidelines and address regional disparities in healthcare access and practice patterns. Existing guidelines from societies such as the European Society of Gastrointestinal Endoscopy, the American Society for Gastrointestinal Endoscopy, and the British Society of Gastrointestinal Endoscopy provide risk-stratified frameworks for procedure-specific antithrombotic management, yet their adoption varies globally. Eastern practices often prioritize shorter warfarin cessation windows (e.g., 3 days for routine colonoscopies in China), contrasting with Western protocols that align more closely with international guidelines. Future directions emphasize integrating artificial intelligence into clinical workflows to personalize risk assessments and adopting telemedicine platforms for real-time decision support. Addressing these gaps is critical to reducing thromboembolic and hemorrhagic complications in high-risk patients undergoing endoscopic procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.